. 2016 Feb 2;7(11):12525–12536. doi: 10.18632/oncotarget.7123

Table 3. Frequency of BCP A1762T/G1764A dual mutations from chronic HBV-infected patients, including HCC.

Comparisons	Studies	A1762T/G1764A dual mutation, n (%)	Heterogeneity				OR	95% CI	P value
Comparisons	Studies	A1762T/G1764A dual mutation, n (%)	Chi²	df	P	I² (%)	OR	95% CI	P value
HCC	[4-38, 40-55]	2480/3729 (66.5)	270.4	50	< 0.00001	82	3.05	2.35-3.95	< 0.00001
Non-HCC	[4-38, 40-55]	2594/6511 (39.8)	270.4	50	< 0.00001	82	3.05	2.35-3.95	< 0.00001
HCC	[5, 9, 12-14, 16, 18, 23, 25, 28, 30, 34, 36, 41, 46-48, 51, 55]	544/808 (67.3)	33.38	18	0.02	46	1.55	1.06-2.26	0.02
LC		441/708 (62.3)	33.38	18	0.02	46	1.55	1.06-2.26	0.02
HCC	[5, 9, 12, 13, 20-23, 25, 28-30, 33, 34, 36, 41, 47, 48, 51, 53, 55]	927/1300 (71.3)	72.49	20	< 0.00001	72	2.87	1.96-4.20	< 0.00001
CHB		796/1566 (50.8)	72.49	20	< 0.00001	72	2.87	1.96-4.20	< 0.00001
HCC	[5, 7-9, 16, 17, 22-25, 30, 31, 36, 41, 44, 51]	591/924 (64.0)	70.33	15	< 0.00001	79	5.59	3.17-9.83	< 0.00001
ASC	[5, 7-9, 16, 17, 22-25, 30, 31, 36, 41, 44, 51]	246/1068 (23.0)	70.33	15	< 0.00001	79	5.59	3.17-9.83	< 0.00001
LC-HCC	[12, 16, 47, 54]	327/476 (68.7)	6.57	3	0.09	54	2.06	0.99-4.28	0.05
Non-LC-HCC	[12, 16, 47, 54]	93/165 (56.4)	6.57	3	0.09	54	2.06	0.99-4.28	0.05
Non-LC-HCC	[12, 16, 47, 54]	93/165 (56.4)	7.60	3	0.05	61	2.16	1.08-4.32	0.03
CHB/ASC	[12, 16, 47, 54]	225/466 (48.3)	7.60	3	0.05	61	2.16	1.08-4.32	0.03

Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; CHB, chronic hepatitis B; ASC, asymptomatic HBsAg carriers; LC-HCC, cirrhotic hepatocellular carcinoma; Non-LC-HCC, non-cirrhotic hepatocellular carcinoma.